|Year : 2017 | Volume
| Issue : 2 | Page : 193-195
Reactivation pulmonary tuberculosis in two patients treated with pirfenidone
Mohammad Khan, Majed Alghamdi, Hamdan AL-Jahdali
Department of Medicine, Division of Pulmonary, King Saud bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City, Riyadh, Saudi Arabia
|Date of Web Publication||19-May-2017|
Department of Medicine, Division of Pulmonary, King Abdulaziz Medical City, P. O. Box 22490, Riyadh 11426
Source of Support: None, Conflict of Interest: None
We report two cases of patients with biopsy-proven idiopathic pulmonary fibrosis (IPF) who were treated with new antifibrotic agent for pirfenidone for more than 12 months. Both cases developed cavitary pulmonary tuberculosis (TB) proven by positive sputum TB culture. Both cases were treated with standard anti-TB drugs for 9 months and had complete clinical and radiological resolution. To our knowledge, these are the first reported human cases of patients with IPF who have been on pirfenidone and developed cavitary pulmonary TB.
Keywords: Idiopathic pulmonary fibrosis, pirfenidone, tuberculosis
|How to cite this article:|
Khan M, Alghamdi M, AL-Jahdali H. Reactivation pulmonary tuberculosis in two patients treated with pirfenidone. Int J Mycobacteriol 2017;6:193-5
|How to cite this URL:|
Khan M, Alghamdi M, AL-Jahdali H. Reactivation pulmonary tuberculosis in two patients treated with pirfenidone. Int J Mycobacteriol [serial online] 2017 [cited 2021 Apr 18];6:193-5. Available from: https://www.ijmyco.org/text.asp?2017/6/2/193/206612
| Introduction|| |
Pirfenidone is an orally available antifibrotic drug approved by the Food and Drug Administration (FDA) in 2014 for the treatment of idiopathic pulmonary fibrosis (IPF). It has significant antifibrotic and anti-inflammatory effects.
The precise mechanism of action of pirfenidone is not fully understood but thought to inhibit transforming growth factor (TGF)-dependent collagen production, decreased fibroblastic foci, and blocking platelet-derived growth factor and decreasing fibroblast proliferation.
In mice experimental model with induced chronic pulmonary tuberculosis (PTB), adding pirfenidone to slandered anti-TB regimen results in incomplete sterilization of TB. In addition, adjunctive pirfenidone treatment results in the development of persistent pulmonary cavitation, pulmonary consolidation corresponding to lobar pneumonia early in the course of disease, and induce drug resistance in this mice experimental model. These observations strongly suggest that pirfenidone affects host control of TB infection through marked increase in matrix metalloproteinase.
The incidence and mortality of PTB are high among patient with IPF.,, Multiple conducted clinical trials of pirfenidone did not report an increase in either incidence or reactivation of TB; however, these trials were conducted in low TB prevalence regions. We report PTB reactivation in two IPF patients treated with pirfenidone.
| Case Reports|| |
A 64-year-old woman originally presented with cough and shortness of breath in February 2015. Her subsequent investigations with computed tomography (CT) chest and video-assisted thoracoscopic surgical (VATS) confirmed usual interstitial pneumonia-IPF (UIP/IPF). She was discussed in our interstitial lung disease (ILD) multidisciplinary meeting, and consensuses were to start her on pirfenidone according to her weight. She was put on 1800 mg in three divided doses in March 2015 and had regular follow-up in our ILD clinic. Twelve months after the initiation of pirfenidone, she presented with cough, fever, and weight loss to our emergency room. The chest X-ray and CT scan of her chest have shown a large cavitary lesion in the right upper lobe [Figure 1]a. Subsequent workup with bronchoscopy and bronchoalveolar lavage has confirmed smear- and polymerase chain reaction (PCR)-positive TB. Subsequently, the mycobacterium TB (MTB) was shown to be pansensitive to first-line anti-TB treatment. Her HIV status was shown to be negative. The patient received 9 months of standard treatment with four drugs initiation and two drugs continuation for subsequent 7 months. She made a full recovery follow-up CT showing significant improvement [Figure 1]b.
|Figure 1: (a) Cavitary lesion of confirmed pulmonary tuberculosis diagnosis in the right upper lobe postpirfenidone therapy. (b) Resolution of the cavitary lesion with posttuberculosis pleural thickening and fibrosis.|
Click here to view
A 58-year-old man was diagnosed with UIP/IPF based on clinic radiological and VATS biopsy in 2014. He opted for treatment with pirfenidone and started at 2400 per day in divided doses since January 2015. After he has been on pirfenidone for 20 months, he presented with cough and his CT scan in follow-up clinic [Figure 2]a showed a large cavitating lesion in the left upper lobe. The sputum induction in this case has shown smear- and PCR-positive TB that was subsequently confirmed to be pansensitive MTB. He received 7 months of treatment with standard anti-TB and had resolution of his CT changes [Figure 2]b and clinical improvement. His HIV status was negative.
|Figure 2: (a) Cavitary lesion of confirmed pulmonary tuberculosis diagnosis in the left upper lobe postpirfenidone therapy. (b) Resolution of the cavitary lesion with posttuberculosis therapy.|
Click here to view
| Discussion|| |
Pirfenidone is an oral antifibrotic agent that was approved by FDA in 2014 for the treatment of IPF. The drug is shown to have antifibrotic and anti-inflammatory properties in multiple phase 3 clinical trials that resulted in preserving the lung functions and hence slow down disease progression. The precise mechanism of action of pirfenidone is not fully understood but thought to inhibit TGF-beta1-dependent collagen production, decreased fibroblastic foci, and blocking platelet-derived growth factor.
Patients with IPF are known to have high incidence of PTB. PTB is known to causes lung injury, fibrosis, and cavitations. The TB granuloma is known to harbor tuberculous bacilli for decades without causing active disease, depending on tuberculous bacilli pathogenicity and host factors; future reactivation leads to causation, cavitations, and TB activation.
There are research studies in animal models that have proven that pirfenidone promotes pulmonary cavitation and drug resistance in mouse models with TB. Furthermore, pirfenidone has immune-modulating activities, by altering T-cell proliferation and cytokine release in response to T-cell receptor. We believe to our knowledge no human cases are reported to develop cavitary TB while on pirfenidone at the same time. Our two cases were diagnosed IPF based on clinic, radiological, and histological data. The decision was taken to start them on pirfenidone standard dose, and they were clinically followed up. There was no account of past PTB or any exposure to any other immunosuppressive treatment in the interim period. The workup before the start of pirfenidone cases has not led to any suspicion of underlying PTB infection. Both cases suffered from pansensitive MTB and responded well to anti-TB treatment. Most of the clinical trial done on pirfenidone was in low incidence countries for TB. The reported annual TB incidence rate of 18/100,000 population in Saudi Arabia therefore considered in the medium-risk countries for TB. These cases would imply that pirfenidone has probably led to reactivation of probable latent TB. Although we are not certain that pirfenidone is the cause of TB reactivation, it certainly may contribute to TB reactivation. This is needed to be confirmed by doing a prospective study. However, it will be strongly advised to carefully watch patient for developing any features of TB infection when commenced on antifibrotic, especially pirfenidone in medium to high TB burden countries, especially with the increase incidence of IPF and wider use of treatment with antifibrotics specially pirfenidone.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011;20:85-97.
Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 2010;3:16.
Ahidjo BA, Maiga MC, Ihms EA, Maiga M, Ordonez AA, Cheung LS, et al.
The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis. JCI Insight 2016;1:e86017.
Chung MJ, Goo JM, Im JG. Pulmonary tuberculosis in patients with idiopathic pulmonary fibrosis. Eur J Radiol 2004;52:175-9.
Shachor Y, Schindler D, Siegal A, Lieberman D, Mikulski Y, Bruderman I. Increased incidence of pulmonary tuberculosis in chronic interstitial lung disease. Thorax 1989;44:151-3.
Park SW, Song JW, Shim TS, Park MS, Lee HL, Uh ST, et al.
Mycobacterial pulmonary infections in patients with idiopathic pulmonary fibrosis. J Korean Med Sci 2012;27:896-900.
King TE Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. J Infect Dis 2005;192:1201-9.
Visner GA, Liu F, Bizargity P, Liu H, Liu K, Yang J, et al.
Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation 2009;88:330-8.
Al-Hajoj S, Varghese B. Tuberculosis in Saudi Arabia: The journey across time. J Infect Dev Ctries 2015;9:222-31.
[Figure 1], [Figure 2]